Insider trade

Director sold ~$14.8M of ROIV shares in the open market

Traded Dec 16, 2025 · Filed Dec 19, 2025

Why it stands out

A board member of Roivant Sciences sold $14.8M of Roivant Sciences shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

DirectorIndirect holding$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$14,823,869

Shares × reported transaction price

Timing vs results

36 days after results of Nov 10, 2025, 52 days before results of Feb 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−4.3%	+0.4%	−4.8%
30 days	+1.3%	+0.1%	+1.2%
90 days	+23.1%	−4.3%	+27.4%
180 days	+37.8%	+8.7%	+29.1%

Past results only. Not a forecast.

The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

9mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale9mo ago

9mo ago

Derivative exercise or conversion — not an open-market buy.